Literature DB >> 20232343

Molecular targets of [6]-gingerol: Its potential roles in cancer chemoprevention.

Ademola A Oyagbemi1, Adebowale B Saba, Odunayo I Azeez.   

Abstract

A wide variety of phenolic compounds derived from spices possess potent antioxidant, anti-inflammatory, antimutagenic, and anticarcinogenic activities. [6]-gingerol (1-[4'-hydroxy-3'-methoxyphenyl]-5-hydroxy-3-decanone) is the major pungent principle of ginger, with numerous pharmacological properties including antioxidant, anti-inflammation, and antitumor promoting properties. It could decrease inducible nitric oxide synthase (iNOS) and tumor necrosis factor alpha (TNF-alpha) expression through suppression of I-kappaB alpha (IkappaBalpha) phosphorylation, nuclear factor kappa B (NF-kappaB) nuclear translocation. Other antiproliferative mechanisms of [6]-gingerol include the release of Cytochrome c, Caspases activation, and increase in apoptotic protease-activating factor-1 (Apaf-1) as mechanism of apoptosis induction. Taken together, the chemopreventive potentials of [6]-gingerol present a promising future alternative to therapeutic agents that are expensive, toxic, and might even be carcinogenic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232343     DOI: 10.1002/biof.78

Source DB:  PubMed          Journal:  Biofactors        ISSN: 0951-6433            Impact factor:   6.113


  21 in total

1.  Examination of the pharmacokinetics of active ingredients of ginger in humans.

Authors:  Yanke Yu; Suzanna Zick; Xiaoqin Li; Peng Zou; Benjamin Wright; Duxin Sun
Journal:  AAPS J       Date:  2011-06-03       Impact factor: 4.009

2.  Development of UPLC Fingerprint with Multi-Component Quantitative Analysis for Quality Consistency Evaluation of Herbal Medicine "Hyangsapyeongwisan".

Authors:  Dipak Kumar Sharma; Se-Gun Kim; Ramakanta Lamichhane; Kyung-Hee Lee; Amrit Poudel; Hyun-Ju Jung
Journal:  J Chromatogr Sci       Date:  2015-12-27       Impact factor: 1.618

Review 3.  The Role of Secondary Metabolites on Gynecologic Cancer Therapy: Some Pathways and Mechanisms.

Authors:  Mürşide Ayşe Demirel; İpek Süntar
Journal:  Turk J Pharm Sci       Date:  2017-11-20

4.  Shogaol overcomes TRAIL resistance in colon cancer cells via inhibiting of survivin.

Authors:  Jung Soon Hwang; Hai-Chon Lee; Sang Cheul Oh; Dae-Hee Lee; Ki Han Kwon
Journal:  Tumour Biol       Date:  2015-06-11

5.  Gingerol sensitizes TRAIL-induced apoptotic cell death of glioblastoma cells.

Authors:  Dae-Hee Lee; Dong-Wook Kim; Chang-Hwa Jung; Yong J Lee; Daeho Park
Journal:  Toxicol Appl Pharmacol       Date:  2014-07-14       Impact factor: 4.219

6.  Gingerol protects against experimental liver fibrosis in rats via suppression of pro-inflammatory and profibrogenic mediators.

Authors:  Mardi M Algandaby; Ali M El-Halawany; Hossam M Abdallah; Abdulrahman M Alahdal; Ayman A Nagy; Osama M Ashour; Ashraf B Abdel-Naim
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-26       Impact factor: 3.000

Review 7.  Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability.

Authors:  Hu Wang; Tin Oo Khor; Limin Shu; Zheng-Yuan Su; Francisco Fuentes; Jong-Hun Lee; Ah-Ng Tony Kong
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

Review 8.  A comprehensive review on pharmacotherapeutics of herbal bioenhancers.

Authors:  Ghanshyam B Dudhatra; Shailesh K Mody; Madhavi M Awale; Hitesh B Patel; Chirag M Modi; Avinash Kumar; Divyesh R Kamani; Bhavesh N Chauhan
Journal:  ScientificWorldJournal       Date:  2012-09-17

9.  Study on the hypochlolesterolemic and antioxidative effects of tyramine derivatives from the root bark of Lycium chenese Miller.

Authors:  Sung-Hee Cho; Eun-Jung Park; Eun-Ok Kim; Sang-Won Choi
Journal:  Nutr Res Pract       Date:  2011-10-28       Impact factor: 1.926

10.  Attenuation of Proinflammatory Responses by S-[6]-Gingerol via Inhibition of ROS/NF-Kappa B/COX2 Activation in HuH7 Cells.

Authors:  Xiao-Hong Li; Kristine C Y McGrath; Van H Tran; Yi-Ming Li; Colin C Duke; Basil D Roufogalis; Alison K Heather
Journal:  Evid Based Complement Alternat Med       Date:  2013-06-16       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.